2024 CASH | Professor Tao Cheng: Misaligned Development, Collaborative Innovation – A Discussion on High-Quality Development in Hematology Against the Backdrop of the Innovation Era

2024 CASH | Professor Tao Cheng: Misaligned Development, Collaborative Innovation – A Discussion on High-Quality Development in Hematology Against the Backdrop of the Innovation Era

2024.03.04
The Fourth China Hematology Development Conference was held in Tianjin from January 5th to 7th, 2024. Themed "Broadening Hematology, Healthcare, and Wellness," the conference focused on the core development directions of the hematology discipline and engaged in discussions and sharing of hot topics and cutting-edge issues in basic hematology research, translation, and clinical diagnosis and treatment in the new era. During the conference, Professor Tao Cheng, the chairman of the conference and the director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared the highlights of the event in an interview.

Website Disclaimer

2024.03.02
Content marked as original on the "Infectious Disease Frontier" platform holds copyright under Infectious Disease Frontier. While we encourage sharing and reproduction of our content, it must be done with prior written consent from Infectious Disease Frontier. Unauthorized use is strictly prohibited, and legal action may be taken against infringement.
The Role of Fanconi Anemia Signaling Pathway Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Insights from Mutation Spectrum, Expression Profiling, and Prognosis Evaluation

The Role of Fanconi Anemia Signaling Pathway Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Insights from Mutation Spectrum, Expression Profiling, and Prognosis Evaluation

2024.03.01
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Med Genomics. The title of the study is "Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia". The study sheds light on the complex interplay between Fanconi anemia (FA) signaling pathway genes and the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Pediatric Acute Myeloid Leukemia and Hyperleukocytosis: Prognostic Impact of High White Blood Cell Counts

Pediatric Acute Myeloid Leukemia and Hyperleukocytosis: Prognostic Impact of High White Blood Cell Counts

2024.03.01
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Current Opinion In Pediatrics. The title of the study is "Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy". The study represents a significant prognostic challenge in pediatric AML, with recent research shedding light on its complex implications for clinical outcomes.
Iron Chelation Therapy in Myelodysplastic Syndrome Mice: A Study on Erythropoiesis and Iron Overload

Iron Chelation Therapy in Myelodysplastic Syndrome Mice: A Study on Erythropoiesis and Iron Overload

2024.03.01
In December 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Elife. The title of the study is "Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice". The  study provides robust evidence for the effectiveness of iron chelation therapy, particularly with deferiprone (DFP), in mitigating anemia and reducing iron overload in a mouse model of myelodysplastic syndrome (MDS).
Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematological Diseases

Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematological Diseases

2024.03.01
In May 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Frontiers in Cellular and Infection Microbiology. The title of the study is "Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases". This study emphasizes the importance of identifying high-risk MDR infections and selecting appropriate antibiotic therapy to improve patient survival.